sansalvamide A peptide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: sansalvamide A peptide
• 英文别名: sansalvamide A amide；sansalvamide A-amide；sansalvamide A；cyclo-(L-Phe-L-Leu-L-Val-L-Leu-L-Leu)；San A-amide；(3S,6S,9S,12S,15S)-3-benzyl-6,12,15-tris(2-methylpropyl)-9-propan-2-yl-1,4,7,10,13-pentazacyclopentadecane-2,5,8,11,14-pentone
• 化学式: C₃₂H₅₁N₅O₅
• 分子量: 585.787
• InChiKey: GZKGGHUTCBGDES-IRGGMKSGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  42
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.66
• 拓扑面积：
  146
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  L-苯丙氨酸甲酯 在 N,N-二异丙基乙胺 盐酸 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 苯甲醚 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 、 三氟乙酸 、 3-(二乙氧基邻酰氧基)-1,2,3-苯并三嗪-4-酮 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 98.0h， 生成 sansalvamide A peptide
  参考文献：
  名称：

  Sansalvamide A衍生物的合成及其在MSS结肠癌细胞系HT-29中的细胞毒性。

  摘要：

  我们报告了36种Sansalvamide A衍生物的合成及其对结肠癌HT-29细胞系（一种微卫星稳定（MSS）结肠癌细胞系）的生物活性。这三十六种化合物可分为三个子集，其中化合物的第一子集包含L-氨基酸，第二个子集包含D-氨基酸，而第三子集包含D-和L-氨基酸。五种化合物表现出出色的抑制活性（抑制率> 75％）。化合物的结构活性关系（SAR）确定了位置2或3上的单个D-氨基酸比Sansalvamide A肽的细胞毒性提高了10倍。这项工作强调了残基2和3的重要性以及D-氨基酸在该类化合物的非常规SAR中的作用。

  DOI：

  10.1016/j.bmc.2006.04.031

文献信息

• High-yielding macrocyclization conditions used in the synthesis of novel Sansalvamide A derivatives
  作者：Thomas J. Styers、Rodrigo Rodriguez、Po-Shen Pan、Shelli R. McAlpine

  DOI：10.1016/j.tetlet.2005.11.056

  日期：2006.1

  Described are the syntheses of nine Sansalvamide A derivatives using new, high-yielding, in situ deprotection–cyclization conditions that are general for this series of macrocycles, 55% average for both steps. This is 10-fold greater than previously reported yields.

  描述了使用新的，高产的，原位脱保护-环化条件合成的九种Sansalvamide A衍生物，该条件对于该系列大环化合物而言是通用的，两个步骤的平均值均为55％。这是以前报道的产量的十倍。
• Cyclic Peptide Antitumor Agents
  申请人：Silverman Richard B.

  公开号：US20100204088A1

  公开（公告）日：2010-08-12

  Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.

  环肽化合物及其衍生物通过治疗人黑色素瘤、胰腺癌、乳腺癌、前列腺癌细胞表现出抗肿瘤活性。
• CYCLIC PEPTIDE ANTITUMOR AGENTS
  申请人：Silverman Richard B.

  公开号：US20120122799A1

  公开（公告）日：2012-05-17

  Cyclic peptide compounds and derivatives thereof having antitumor activity as shown by treatment of human melanoma, pancreatic, breast, prostate cancer cells.

  环肽化合物及其衍生物具有抗肿瘤活性，可通过治疗人类黑色素瘤、胰腺癌、乳腺癌和前列腺癌细胞来展示。
• Synthesis and Cytotoxicity of Novel Sansalvamide A Derivatives
  作者：Chris L. Carroll、Jennifer V. C. Johnston、Ahmet Kekec、Joseph D. Brown、Emily Parry、Julia Cajica、Irene Medina、Kristina M. Cook、Ricardo Corral、Po-Shen Pan、Shelli R. McAlpine

  DOI：10.1021/ol051161g

  日期：2005.8.1

  [GRAPHICS]Described are the syntheses of 14 derivatives of the natural product Sansalvamide A, where two are more active against HCT 116 colon cancer cell lines than the natural product. These derivatives were synthesized using a combinatorial-type strategy that permits elucidation of the amino acid role in the cytotoxicity, and they lay the groundwork for development of new anticancer agents.
• Comprehensive Study of Sansalvamide A Derivatives and their Structure–Activity Relationships against Drug-Resistant Colon Cancer Cell Lines
  作者：Katerina Otrubova、Gerald Lushington、David Vander Velde、Kathleen L. McGuire、Shelli R. McAlpine

  DOI：10.1021/jm070731a

  日期：2008.2.1

  We report an extensive structure-activity relationship (SAR) of 62 compounds active against two drug-resistant colon cancer cell lines. Our comprehensive evaluation of two generations of compounds utilizes SAR, NMR, and molecular modeling to evaluate the key 3D features of potent compounds. Of the seven most potent compounds reported here, five are second-generation, emphasizing our ability to incorporate potent features found in the first generation and utilize their structures to design potency into the second generation. These analogs share no structural homology to current colon cancer drugs, are cytotoxic at levels on par with existing drugs treating other cancers, and demonstrate selectivity for drug-resistant colon cancer cell lines over noncancerous cell lines. Thus, we have established sansalvamide A as an excellent lead for treating, multiple drug-resistant colon cancers.